Zika virus (ZIKV), which is associated with microcephaly in infants and Guillain-Barré 18 syndrome, reemerged as a serious public health threat in Latin America in recent years. Previous 19 high-throughput screening (HTS) campaigns have revealed several potential hit molecules against 20 ZIKV, including methotrexate (MTX), which is clinically used as an anti-cancer chemotherapy and 21 anti-rheumatoid agent. We studied the mechanism of action of MTX against ZIKV in relation to its 22 inhibition of dihydrofolate reductase (DHFR) in vitro using Vero and human neural stem cells 23 (hNSCs). As expected, an antiviral effect for MTX against ZIKV was observed, showing up to ten-24 fold decrease in virus titer during MTX treatment. We also observed that addition of leucovorin (a 25 downstream metabolite of DHFR pathway) rescued the ZIKV replication impaired by MTX 26 treatment in ZIKV-infected cells, explaining the antiviral effect of MTX through inhibition of DHFR.
arthritis, and rheumatoid arthritis [9] [10] [11] . As a chemotherapy agent, the main function of MTX is to antagonize dihydrofolate reductase (DHFR) to decrease de novo synthesis of purines and pyrimidines 48 [12, 13] , thereby inhibiting the viability of highly replicating cells. Also, MTX has been reported to 49 interfere with a variety of cellular mechanisms, such as oxidative stress or cellular differentiation via 50 methylation [14, 15] .
51
Interestingly, DHFR inhibitors have also been investigated to treat infectious diseases. Due to its 52 formation of a specific dimer with thymidylate synthase (TS) [16] , protozoan DHFR has been studied 53 as a drug target to treat parasitic diseases [17] . As antiviral agents, MTX and the antimetabolite 54 floxuridine have been shown to decrease the replication of DENV through inhibition of host DHFR 55 and TS enzymes [18] . Here, we demonstrate the antiviral activity of MTX against ZIKV and probe its 56 mechanism of action using downstream metabolites of the DHFR pathway, leucovorin and 57 adenosine. 
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When 100% confluency of Vero cells was reached, the initial medium was removed, and the cells 71 were infected with ZIKV at multiplicity of infection (MOI) of 0.5. At 24h post-infection (PI), the initial 72 medium was removed, and fresh medium was added. At 48h PI, the medium was collected and spun 73 down at 1500 rpm for 10 minutes. The supernatant was collected, 1% DMSO was added, and the 74 sample was stored at -80℃. The titer of the virus stock was measured by plaque assay.
75

Plaque Assay
76
Vero cells were seeded at a density of 30,000 cells/well on a 96-wells plate (Corning) and 77 incubated at 37°C and 5% CO2 for 24h before infection. Each ZIKV sample was diluted by ten-fold 78 serial dilution, added to Vero cells in at least duplicate, then incubated for 1h. After incubation, media 79 with virus dilutions were removed from the cells, and ZIKV-infected Vero cells were covered with 80 an overlay consisting of DMEM with 0.35% UltraPure agarose (Life Sciences). The plates were further 81 incubated for 72h and fixed with 37% formaldehyde overnight. After fixation, the agarose overlay 82 was aspirated, and fixed cell monolayer was stained with 0.25% crystal violet. For each sample, the 83 titer of ZIKV was reported in PFU/mL.
84
Immunofluorescence Imaging
85
Vero cells were seeded at a density of 30,000 cells/well in an opaque black 96-wells plate 86 (Corning) and incubated at 37°C and 5% CO2 for 24h before infection. Then, Vero cells were infected 87 with ZIKV at MOI of 0.2. The infected Vero cells were incubated for 48h then fixed with 4% 88 formaldehyde in phosphate buffered saline (PBS). After fixation, the cells were permeabilized with 89 0.2% TritonX-100 in PBS for 5 min, then blocked with 1% bovine serum albumin (BSA) (Amresco) in 90 PBS for 30 min at room temperature. After blocking, the cells were incubated with diluted primary 91 antibody, anti-flavivirus group antigen primary antibody, clone D1-4G2-4-15 (Millipore 92 #MAB10216)), in PBS with 1% BSA and 0.1% TritonX-100 at 4°C overnight. The cells were washed with PBS three times and treated with diluted secondary antibody, goat anti-mouse Alexa Fluor 594 94 (ThermoFisher Scientific #A-11032), in PBS with 1% BSA for 1h at room temperature while covered 95 with aluminum foil. The cells were then washed with PBS three times and stained with SYTOX Green 96 (ThermoFisher Scientific #R37168) to visualize nuclei. Immunofluorescence images of cells were 97 acquired using a ZEISS Fluorescence Microscope (Carl Zeiss, Jena, Germany, Axio Vert A1), and 98 images were taken using Zen2 Software. The images were processed with ImageJ 99 (https://imagej.nih.gov/ij/). To test the rescue effect of leucovorin on ZIKV replication with MTX treatment, Vero cells and 110 hNSCs were seeded in a 96-wells plate (Corning) at a cell density of 30,000 and 10,000 cells/well, 111 respectively. The Vero cells and hNSCs were then infected with ZIKV at MOI 0.2 and 0.1, respectively, 112 and simultaneously treated with 5μM MTX, or a combination of 5μM MTX with 50μM folic acid 113 (Sigma #F7876) or leucovorin (Sigma #F7878). The cells were further incubated for 48h at 37°C and 114 5% CO2. After incubation, the supernatant was collected to measure the virus titer. The cells were 115 then treated under the same conditions as described above but without ZIKV infection to assess the 116 effect of leucovorin on countering the cytotoxic effects of MTX on the cells. Then, the cell viability 117 was measured using CTG (Promega) reagent.
118
Rescue Effect of GAT Medium on ZIKV Replication and Cell Viability from Methotrexate
119
To test the rescue effect of GAT medium (Glycine, Adenosine, and Thymidine, Sigma #410225, 120 #A4036 and #T1895, respectively) on MTX-mediated suppression of ZIKV replication, Vero cells were 121 seeded in a 96-wells plate at a cell density of 10,000 cells/well. GAT medium was prepared as 122 described previously [19] , in MEM (Gibco) with 10% FCS (Sigma) and 1% PS (Sigma-Aldrich) with a 123 final concentration of 0.67mM glycine, 37.5μM adenosine and 41.3μM thymidine. Vero cells were 124 infected with ZIKV at a MOI 0.2 and simultaneously treated with 5μM MTX in GAT medium. The 125 cells were further incubated for 48h at 37°C and 5% CO2. After incubation, the supernatant was 126 collected to measure the virus titer. Cells were treated under the same conditions as described above To study the cytotoxicity of MTX, we used CTG and CTF reagents for cell viability assays. We 165 tested the compound in different concentrations to calculate CC50 of MTX in the two host cells ( Table   166 1). Using CTG reagent, the CC50 of MTX in Vero cells and hNSCs were calculated to be 0.104μM and 167 0.0163μM, respectively. However, using CTF reagent, the CC50 of MTX in Vero cells and hNSCs were 168 calculated to be both >100μM. The two CC50 values showed drastic variance. Accordingly, to validate 169 which CC50 value is more appropriate, the number of Vero cells were directly counted under 170 microscopy with trypan-blue staining after 0.5μM of MTX treatment (Figure 2A, B) . Although the 171 CC50 of MTX using CTG resulted in a value < 0.5μM, the actual number of Vero cells after 0.5μM MTX 172 treatment did not decrease but rather resulted in slowed cellular growth, supporting the CC50 173 (>100μM) value obtained using the CTF reagent. 
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Relationship between MTX, Folate, and ZIKV Replication
188
To understand the mechanism of action for the antiviral effect of MTX, we proceeded to probe Figure 3A, B) . To study the effect of these three different treatment conditions on Vero 203 host cells, the same experiment was performed with uninfected cells. Using CTG reagent, we 
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Virus titer of HPAN MOI 0.1 on hNSCs was measured by standard plaque assay. (D). The cytotoxicity of 5µM 215 MTX and co-treatment of MTX with 50µM folic acid or leucovorin on Vero cells was studied by CTG reagent.
216
(E). The cytotoxicity of 5µM MTX and co-treatment of MTX with 50µM folic acid or leucovorin on hNSCs was 217 cells was studied by CTG reagent. RLU relative luminescence unit. At least two independent replicates were 218 performed. One-way ANOVA, followed by Tukey's multiple comparisons test, was were used for statistical 
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In this study, we validated MTX as an antiviral targeting ZIKV replication. MTX was previously 247 discovered as a potent hit molecule against ZIKV in human brain microvascular endothelial cells, 
260
MTX can inhibit purine and pyrimidine metabolism, cells treated with MTX showed significantly 261 decreased viability in terms of ATP level. Accordingly, CC50 measurement with CTG reagent also 262 resulted in high cytotoxicity in the two host cells; however, such toxicity could be misleading because 263 the drug mechanism directly interferes with ATP levels, i.e. the readout measurement of the assay.
264
Accordingly, Vero cells with 0.5μM MTX treatment, exceeding the CC50 value obtained from CTG 265 reagent, did not exhibit phenotypic cytotoxicity but rather showed slower cellular replication 
